Pembrolizumab and Nivolumab, which target PD-1, have been applied to patients with melanoma and non-small cell lung cancer (NSCLC) with an objective response rate (ORR) of 40–45% [9–11]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.